Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer

Linda T. Vahdat, Eduard Vrdoljak, Henry Gómez, Rubi Khaw Li, Linda Bosserman, Joseph A. Sparano, Jose Baselga, Pralay Mukhopadhyay, Vicente Valero

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: Data on chemotherapy regimens in elderly patients with metastatic breast cancer (MBC) are limited. The aim of this retrospective pooled analysis was to determine efficacy and safety of ixabepilone plus capecitabine versus capecitabine alone in patients with MBC aged ≥. 65. years. Materials and Methods: A total of 1973 patients with MBC previously treated with or resistant to anthracyclines and taxanes were randomized in two open-label, multinational, phase 3 studies (study 046 and study 048). Patients received ixabepilone (40mg/m2 as a 3-hour intravenous infusion every 3weeks) plus oral capecitabine (1000mg/m2 administered twice each day), or capecitabine alone (1250mg/m2 twice each day). Results: In total, 251 randomized patients were aged ≥. 65. years (ixabepilone plus capecitabine, n=. 116; capecitabine monotherapy, n=. 135). Efficacy results were consistent in patients aged <. 65 and ≥. 65. years with respect to the observed improvement in progression-free survival and objective response rate with ixabepilone plus capecitabine compared with capecitabine alone. No significant differences in overall survival between arms were observed for either subgroup. In the ixabepilone plus capecitabine arm, grade 3/4 hematologic adverse events (AEs) were similar in both subgroups except leukopenia and febrile neutropenia, which had a higher incidence in patients aged ≥. 65. years. The majority of grade 3/4 nonhematologic AEs were similar in the two subgroups, including fatigue, peripheral sensory neuropathy, and hand-foot syndrome. Conclusion: The combination of ixabepilone plus capecitabine maintains its efficacy in elderly patients with anthracycline and taxane pretreated MBC, with a similar safety profile to patients aged <. 65. years.

Original languageEnglish (US)
Pages (from-to)346-352
Number of pages7
JournalJournal of Geriatric Oncology
Volume4
Issue number4
DOIs
StatePublished - Oct 2013

Fingerprint

Anthracyclines
Breast Neoplasms
Safety
taxane
ixabepilone
Capecitabine
Hand-Foot Syndrome
Taxoids
Febrile Neutropenia
Leukopenia
Peripheral Nervous System Diseases
Intravenous Infusions
Disease-Free Survival
Fatigue
Drug Therapy
Survival

Keywords

  • Capecitabine
  • Elderly patients
  • Ixabepilone
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Oncology

Cite this

Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. / Vahdat, Linda T.; Vrdoljak, Eduard; Gómez, Henry; Li, Rubi Khaw; Bosserman, Linda; Sparano, Joseph A.; Baselga, Jose; Mukhopadhyay, Pralay; Valero, Vicente.

In: Journal of Geriatric Oncology, Vol. 4, No. 4, 10.2013, p. 346-352.

Research output: Contribution to journalArticle

Vahdat, Linda T. ; Vrdoljak, Eduard ; Gómez, Henry ; Li, Rubi Khaw ; Bosserman, Linda ; Sparano, Joseph A. ; Baselga, Jose ; Mukhopadhyay, Pralay ; Valero, Vicente. / Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. In: Journal of Geriatric Oncology. 2013 ; Vol. 4, No. 4. pp. 346-352.
@article{cfaf14f998b84edb9f942c2aeffc70e2,
title = "Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer",
abstract = "Objectives: Data on chemotherapy regimens in elderly patients with metastatic breast cancer (MBC) are limited. The aim of this retrospective pooled analysis was to determine efficacy and safety of ixabepilone plus capecitabine versus capecitabine alone in patients with MBC aged ≥. 65. years. Materials and Methods: A total of 1973 patients with MBC previously treated with or resistant to anthracyclines and taxanes were randomized in two open-label, multinational, phase 3 studies (study 046 and study 048). Patients received ixabepilone (40mg/m2 as a 3-hour intravenous infusion every 3weeks) plus oral capecitabine (1000mg/m2 administered twice each day), or capecitabine alone (1250mg/m2 twice each day). Results: In total, 251 randomized patients were aged ≥. 65. years (ixabepilone plus capecitabine, n=. 116; capecitabine monotherapy, n=. 135). Efficacy results were consistent in patients aged <. 65 and ≥. 65. years with respect to the observed improvement in progression-free survival and objective response rate with ixabepilone plus capecitabine compared with capecitabine alone. No significant differences in overall survival between arms were observed for either subgroup. In the ixabepilone plus capecitabine arm, grade 3/4 hematologic adverse events (AEs) were similar in both subgroups except leukopenia and febrile neutropenia, which had a higher incidence in patients aged ≥. 65. years. The majority of grade 3/4 nonhematologic AEs were similar in the two subgroups, including fatigue, peripheral sensory neuropathy, and hand-foot syndrome. Conclusion: The combination of ixabepilone plus capecitabine maintains its efficacy in elderly patients with anthracycline and taxane pretreated MBC, with a similar safety profile to patients aged <. 65. years.",
keywords = "Capecitabine, Elderly patients, Ixabepilone, Metastatic breast cancer",
author = "Vahdat, {Linda T.} and Eduard Vrdoljak and Henry G{\'o}mez and Li, {Rubi Khaw} and Linda Bosserman and Sparano, {Joseph A.} and Jose Baselga and Pralay Mukhopadhyay and Vicente Valero",
year = "2013",
month = "10",
doi = "10.1016/j.jgo.2013.07.006",
language = "English (US)",
volume = "4",
pages = "346--352",
journal = "Journal of Geriatric Oncology",
issn = "1879-4068",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer

AU - Vahdat, Linda T.

AU - Vrdoljak, Eduard

AU - Gómez, Henry

AU - Li, Rubi Khaw

AU - Bosserman, Linda

AU - Sparano, Joseph A.

AU - Baselga, Jose

AU - Mukhopadhyay, Pralay

AU - Valero, Vicente

PY - 2013/10

Y1 - 2013/10

N2 - Objectives: Data on chemotherapy regimens in elderly patients with metastatic breast cancer (MBC) are limited. The aim of this retrospective pooled analysis was to determine efficacy and safety of ixabepilone plus capecitabine versus capecitabine alone in patients with MBC aged ≥. 65. years. Materials and Methods: A total of 1973 patients with MBC previously treated with or resistant to anthracyclines and taxanes were randomized in two open-label, multinational, phase 3 studies (study 046 and study 048). Patients received ixabepilone (40mg/m2 as a 3-hour intravenous infusion every 3weeks) plus oral capecitabine (1000mg/m2 administered twice each day), or capecitabine alone (1250mg/m2 twice each day). Results: In total, 251 randomized patients were aged ≥. 65. years (ixabepilone plus capecitabine, n=. 116; capecitabine monotherapy, n=. 135). Efficacy results were consistent in patients aged <. 65 and ≥. 65. years with respect to the observed improvement in progression-free survival and objective response rate with ixabepilone plus capecitabine compared with capecitabine alone. No significant differences in overall survival between arms were observed for either subgroup. In the ixabepilone plus capecitabine arm, grade 3/4 hematologic adverse events (AEs) were similar in both subgroups except leukopenia and febrile neutropenia, which had a higher incidence in patients aged ≥. 65. years. The majority of grade 3/4 nonhematologic AEs were similar in the two subgroups, including fatigue, peripheral sensory neuropathy, and hand-foot syndrome. Conclusion: The combination of ixabepilone plus capecitabine maintains its efficacy in elderly patients with anthracycline and taxane pretreated MBC, with a similar safety profile to patients aged <. 65. years.

AB - Objectives: Data on chemotherapy regimens in elderly patients with metastatic breast cancer (MBC) are limited. The aim of this retrospective pooled analysis was to determine efficacy and safety of ixabepilone plus capecitabine versus capecitabine alone in patients with MBC aged ≥. 65. years. Materials and Methods: A total of 1973 patients with MBC previously treated with or resistant to anthracyclines and taxanes were randomized in two open-label, multinational, phase 3 studies (study 046 and study 048). Patients received ixabepilone (40mg/m2 as a 3-hour intravenous infusion every 3weeks) plus oral capecitabine (1000mg/m2 administered twice each day), or capecitabine alone (1250mg/m2 twice each day). Results: In total, 251 randomized patients were aged ≥. 65. years (ixabepilone plus capecitabine, n=. 116; capecitabine monotherapy, n=. 135). Efficacy results were consistent in patients aged <. 65 and ≥. 65. years with respect to the observed improvement in progression-free survival and objective response rate with ixabepilone plus capecitabine compared with capecitabine alone. No significant differences in overall survival between arms were observed for either subgroup. In the ixabepilone plus capecitabine arm, grade 3/4 hematologic adverse events (AEs) were similar in both subgroups except leukopenia and febrile neutropenia, which had a higher incidence in patients aged ≥. 65. years. The majority of grade 3/4 nonhematologic AEs were similar in the two subgroups, including fatigue, peripheral sensory neuropathy, and hand-foot syndrome. Conclusion: The combination of ixabepilone plus capecitabine maintains its efficacy in elderly patients with anthracycline and taxane pretreated MBC, with a similar safety profile to patients aged <. 65. years.

KW - Capecitabine

KW - Elderly patients

KW - Ixabepilone

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84884988524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884988524&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2013.07.006

DO - 10.1016/j.jgo.2013.07.006

M3 - Article

VL - 4

SP - 346

EP - 352

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

SN - 1879-4068

IS - 4

ER -